Introduction
Antimicrobial resistance (AMR) within production animal populations is of increasing scientific, public and political concern. A recent review of published literature highlighted that, for some bacteria, AMR patterns seen in humans could be a result of antimicrobial (AM) use in livestock. 1 There are also increasing reports of resistant bacteria being recovered from production animals, [2] [3] [4] [5] that the use of certain classes of antibiotics in livestock increase the risks of multidrug-resistant bacteria being present on farms using these medicines, 6 7 and that decreasing the use of these classes of antimicrobials can reduce the prevalence of resistance on these farms. 8 Fluoroquinolones and third-generation and fourthgeneration cephalosporins have been identified as 'highest priority critically important antimicrobials' (HP-CIAs) for human medicine by national and international bodies including The World health organisation (WHO), World Organisation for Animal Health (OIE) and the Food and Agriculture Organisation of the United Nations (FAO). Several EU countries have already taken steps to reduce AM use in production animal medicine, 9 10 with recent focus on the reduction of HP-CIAs. Prophylactic use of AMs is also under scrutiny as this practice has been demonstrated to increase the prevalence of multidrug-resistant bacteria. 11 Veterinary surgeons (VSs) in the UK have a crucial role to play in the reduction of AM administration on farms: although AMs are commonly administered by farm staff, 12 13 prescription-only veterinary medicines (POM-V), such as AMs, may only be used if prescribed by a VS, who is therefore ultimately responsible for their use. Furthermore, as a trusted source of information to farmers, 13 VSs are well-placed both to implement changes in prescription practice and to educate and motivate farmers and farm staff to engage with disease prevention strategies and more responsible AM use, all of which have been identified as 'areas of action' to reduce AMR. 14 While many VSs understand and appreciate concerns surrounding the use of AMs in production animal medicine, 15 there are also other influences on prescribing practice. Practitioners often feel that they need to respond to farmer expectations of AM prescribing 16 17 and farmers, in turn, have concerns over potential reduced animal health, welfare and production parameters, as well as financial issues associated with reducing or changing AM use on their farms. 13 18 Despite these concerns, a majority of the UK dairy farmers feel that reducing AM use in their dairy herds would be beneficial and could reduce production costs, and that their peers (other farmers and VSs) would think favourably of them doing so. 13 For VSs working in production animal medicine, the challenge of achieving more responsible and sustainable AM use can offer an opportunity to advance dialogue with farmers about on-farm treatment protocols, employing preventive rather than reactive management of animal health and active herd health management.
The primary aim of the study was to investigate the effect of the cessation of use of HP-CIAs, at farm level on associated animal health, welfare and production parameters. Other aims were to describe the reduction in AM use using appropriate metrics and to delineate the process by which prescribing practices were changed on the participating farms. The hypothesis was that cessation of the use of HP-CIAs would not be associated with deterioration of health, welfare or production on the dairy farms investigated. Throughout the study, HP-CIAs are defined according to guidelines from the European Medicines Agency, 19 namely thirdgeneration and fourth-generation cephalosporins, fluoroquinolones and colistin.
Materials and methods
Data collected for this study originated from seven dairy farms, all of which were clients of the Langford Farm Animal Practice (FAP), North Somerset, UK. Data were collected between 1 January 2010 and 31 December 2015.
Implementing prescribing changes
In 2010, VSs at the FAP began an initiative to reduce the use of HP-CIAs on all farms under the care of the practice. During 2010-2011, farmers were engaged and educated about this process through farmer meetings and herd health planning visits; during 2011-2012 changes to prescribing policy and on-farm use were implemented on pilot farms (farms 2 and 3). Subsequently, changes were extended to all farms through the following years (2012) (2013) (2014) (2015) , including one farm that joined the practice at the end of 2013 (farm 6) on which changes in AM use were implemented from January 2014. Despite changes being implemented sequentially across study farms, AM use data were available for all farms for the whole study period. Farms worked closely with different VSs from the practice during this time, but the same changes to prescribing practice were encouraged on all farms throughout this entire process. It was deemed that all substantial changes had been made on all farms by the end of 2014, so at least one year of follow-up data were available for comparison across all farms.
On-farm treatment protocols were changed so that HP-CIAs were not kept on farms and were only prescribed by VSs after examination of an animal. Gradually, the use of HP-CIAs was phased out entirely by both farmers and VSs for any empirical treatment decision. The most significant changes were: (1) from early 2010 fluoroquinolones were no longer used or prescribed by the practice; (2) fourth-generation cephalosporins used in lactating cow intramammary tubes were replaced with products containing penicillin and aminoglycoside preparations; (3) third-generation cephalosporins, widely used as injectable preparations, were replaced with first-generation cephalosporins or aminopenicillins. Practice policy stated that HP-CIAs were only to be considered if indicated by the results of culture and sensitivity testing.
Strategies to encourage and improve animal management and husbandry were also implemented alongside changes in AM use. These included, but were not limited to, the increasing use of medicine audits and reviews to guide herd health planning and engage farmers in changing and reducing AM use, farmer education including evening meetings and practical classes and increased herd health monitoring through clinical scoring (mobility scores/body condition scoring) and sampling (milk cultures, metabolic profiling, etc).
Herd inclusion
Herds were included in this study if they milk recorded monthly and kept sufficiently detailed fertility and disease incidence records to allow analysis of specific health parameters (see online supplementary materials).
Data collection
Health, fertility and milk recording data were captured in Interherd software (Pan Livestock Services, Reading, UK) or bespoke spreadsheets and then either extracted directly from these or after further analysis in another software package (TotalVet, SUM-IT Computer Systems, Thame, UK; Fig  1) . A full explanation of the data collection process and definition of disease parameters are described in the online supplementary materials.
Data for each health and welfare parameter were imported into the R programming environment ( Rprject. org), log-transformed so that regression results represented percentage change per year, and then modelled by random-intercept regression using the Bayesian MCMCglmm package. 20 A total of 130 000 MCMC samples were simulated with the first 30 000 discarded as burn-in. For each health and welfare parameter, the slope of the fitted regression curve as percentage change per year of the mean (M) and the Bayesian equivalent of confidence intervals, the 95 per cent credible interval (CI), are reported.
Antimicrobial prescribing Data collection
Antimicrobial prescribing and sales data were accessed via practice management software (RXWorks, Newbury, UK). From this software, a list of all AM sales to each of the farms in the study was obtained for each of the study years (1 January to 31 December 2010 31 December -2015 . In addition to this, AM sales data were provided by the veterinary practice supplying medicines to farm 6 in 2010-2013. Sales data were entered into a spreadsheet (Microsoft Excel, 2013) for analysis and total kg of AMs used per year as well as Animal Daily Dose per animal per year (ADD), as defined by Dupont and others 21 and mg/ population controlled unit (PCU), 1 were calculated. Further information regarding the calculation of the AM use metrics and AM classification are included in the online supplementary materials.
Prescription data for all AMs, including prescriptions to calves and youngstock were collected, although due to the retrospective nature of the study there was a lack of health data specifically relating to calves, therefore analysis of this data will not be presented in detail.
Results

Farm descriptions
All seven farms were located within a 20 mile radius of Langford FAP in South West England. All farms reared their own heifer replacements, had all-yearround calving patterns and, when housed, kept cows in cubicles (freestalls). All but two farms performed selective dry cow therapy (SDCT) at the start of the study period 22 (see online supplementary materials for SDCT protocol). The farms practising SDCT treated, on average, 36 per cent of cows with AMs. Mean percentage of cows dried off using AMs across all study farms across all years was 53 per cent. Farm 6 began SDCT during 2014. Descriptive information regarding farm management and on-farm data recording are presented in Tables 1 and 2 .
Antimicrobial prescription
In 2010, third-generation and fourth-generation cephalosporins were being prescribed to all seven farms (Fig 2) . None of the six FAP clients was prescribed any fluoroquinolones throughout the study, meaning the reductions seen in HP-CIA use on these farms is solely due to reduced prescriptions of third-generation and fourth-generation cephalosporins. Notably, farm 6 (which became a client of the practice at the end of 2013) was being prescribed a similar amount of HP-CIAs from 2010 to 2013 when compared with farms that were clients of the FAP at this time (Fig 2) . Unlike the other farms, farm 6 was prescribed small quantities of fluoroquinolones in 2011 (0.02 ADD) and 2013 (0.06 ADD). Colistin was not used on any farms throughout the study.
Due to the changes in prescribing practices, the total quantity of HP-CIAs reduced from 0.9 kg or 7.2 ADD in 2010 (accounting for 6.3 per cent and 41.0 per cent of kg and ADD, respectively) until they were not prescribed to any farms in 2015. HP-CIA prescriptions consistently accounted for a larger proportion of ADD than kg of AMs.
The majority of HP-CIAs prescribed in 2010 across the seven farms were licensed for systemic administration (77 per cent kg, 61 per cent ADD; Table 3 ). Intramammary (lactating cow) preparations containing third-generation and fourth-generation cephalosporins also significantly contributed to total quantities of HP-CIAs prescribed (23 per cent kg, 39 per cent ADD), although no dry cow intramammary preparations containing HP-CIAs were prescribed throughout the six years of the study. Overall, systemic AMs accounted for the largest quantities of AM prescriptions to each farm (by both kg and ADD) followed by intramammary preparations. The use of intrauterine and topical AMs was low across all years (Table 3) .
Both metrics show variation in the quantities of AMs being prescribed to the study farms each year; both the total kg of AMs prescribed and the total number of ADD prescribed to the study farms increased in 2012 and 2013 before reducing through 2014 and 2015. When represented in ADD, AM prescription in 2015 was lower than in any previous year of the study (16.7 ADD; Table 3 ).
The mean AM prescription across all study farms was also calculated in mg/PCU for each year of the study and was found to be 14.0, 12.0, 17.5, 18.0, 15.1 and 12.7 mg/PCU, respectively between 2010 and 2015. The minimum value at the farm level was 5.0 mg/ PCU and the maximum value was 35.3 mg/PCU for individual farms across all years of the study.
The increase in the total quantity of AMs prescribed in 2012, as measured in both kg and ADD, was largely due to an increase of penicillins (including penicillin in combination with streptomycin), and first-generation cephalosporins (Table 4) . There was little change in the prescription of antipneumonial AMs considered to be used primarily for the treatment of calves (tetracyclines, chloramphenicol derivatives and macrolides, including long-acting macrolides) over the six years of the study (2.2, 2.0, 1.7, 2.3, 2.1 and 1.8 kg, respectively, through 2010-2015), accounting for 0.1 ADD in 2010 and decreasing to 0.08 ADD in 2015.
Production parameters
Mean 305-day milk yield showed an increasing trend, with a mean increase of 0.6 per cent per year over the six years of the study (95 per cent CI (−0.2 to 1.4); Fig 3) .
Fertility parameters
Fertility parameters showed an improving trend over the course of the six-year study period. Mean 100-day Fig 6) .
Lameness
The percentage of cows scored as lame at mobility scoring sessions performed by VSs decreased over the six years of the study on all farms with complete data (M=−18.2 per cent; 95 per cent CI (−25.5 to -12.5)) (Fig 7) . of the herd culled each year (farm 2), others increased the culling percentage overall (farm 6), and there was variability both within and between farms.
Culling
Discussion
The aims of this study were to describe how prescribing policy was changed to achieve a cessation in HP-CIA use on seven dairy farms, to appropriately assess these AM use changes using two different metrics and to examine the effects of discontinued HP-CIA use on cattle health and welfare. Farms were selected as a convenience sample due to inclusion criteria. It is accepted that for these reasons, and as clients of a first-opinion farm animal practice connected with a veterinary school, these farmers may not be representative of all the UK dairy farms, and may receive more veterinary visits to their farm or veterinary input due to the mutual benefit of providing teaching opportunities for veterinary students. However, all the study farms were commercial dairies and the information outlined in Table 1 demonstrates that these farms represent herd sizes and management systems commonly found in the UK. 23 The potential for similar prescription changes to be made in 'conventional' private practice have also been demonstrated. 24 As these data are only presented from one veterinary practice, the farms are located within a reasonably limited geographic region. While this may have benefits in making the data from the farms more comparable as all will have been influenced similarly by factors such as climate and disease threats, it may mean that these farms are less representative of farms in other locations which are subject to other influences. Tables 1 and 2 demonstrate that a range of different systems and management practices are used across the seven study farms. These differences are likely to influence the initial, and ongoing disease prevalence on the farms (eg, housing type is likely to affect lameness rates and bedding type may influence mastitis rates). However, it is still possible for the aims of the study to be achieved by analysing data from these various farms, demonstrating the effects of the cessation of HP-CIAs on health and production parameters despite differing initial levels or causative factors. This demonstrates that it may be possible to apply similar prescribing changes to farms with a variety of management practices and expect to see health and production parameters maintained, or improved, as they were on these study farms.
In this study, AMs prescribed to farms were assumed to represent AM use. It is possible that some prescribed AMs may not have been administered to animals but may have gone unused or been disposed of. For this reason, AM prescription is likely to overestimate use; however, the authors judged this unlikely to be significant as each farm had weekly or biweekly veterinary visits, making it unnecessary for AMs to be 'stockpiled'.
Calculation of antimicrobial use
The comparison of AM prescribing using two metrics (Tables 3 and 4 of the use of HP-CIAs in intramammary tubes. The way in which the ADD metric is reported alongside kg of AMs prescribed demonstrates the ways in which different analyses of AM use can represent these data differently, as has been described by Mills and others. 25 Calculation of mean AM consumption in mg/PCU values for each year of the study was included to demonstrate the AM prescription of these herds in comparison with the 50 mg/ kg target suggested by the O'Neill report 1 and adopted for the UK across the combined livestock sectors, 26 as well as the Responsible Use of Medicines in Agriculture Alliance (RUMA) Targets Task Force report dairy sector targets of a 50 per cent reduction in use of HP-CIAs between 2015 and 2020 and a total usage target of 21 mg/PCU by 2020. 27 It should be noted that a move away from HP-CIAs towards other AM treatments is likely to initially increase the total mg/kg (or mg/PCU) use due to differences in dose rates. However, if combined with effective changes in herd health management which reduce overall disease incidence, this need not be a long-term effect. Conversely, driving down total mg/kg targets could have unintended consequences if veterinary surgeons were to increase their reliance on low-dose HP-CIAs.
Antimicrobial prescription
Similar to other studies, [28] [29] [30] penicillins and firstgeneration cephalosporins were prescribed in the highest quantity (kg) in 2014 and 2015. Tetracyclines were also commonly prescribed, as has been previously reported. 28 30 Antimicrobial use by the farms in this study differs from that of farms in similar studies, 28 29 in which third-generation and fourth-generation cephalosporins were among the most frequently used AM classes. 29 These findings suggest that the groups of AMs used most frequently by farms in this study (penicillins, first-generation cephalosporins and tetracyclines) are also commonly used on other dairy farms in other developed dairy areas of the world, and, as has been found by other authors, the reduced use of HP-CIAs results in a shift towards the use of penicillins and broad-spectrum AMs. 31 The mean AM prescription to these farms across all years (range 12-18 mg/PCU) was similar to the median and mean AM use on British dairy farms in another recent UK study. After prescribing changes were implemented on farms during 2011-2012, the total quantities of AMs prescribed in kg increased by 52 per cent (table 4) . This was in part due to the differences in mg/dose of firstline antimicrobials and HP-CIAs resulting in the total use of AMs appearing falsely elevated, demonstrated by a smaller increase (25 per cent) as represented by ADD. Improved compliance with treatment protocols as a result of farmer training may also account for some of the changes in total AM prescriptions. However, across both metrics, the quantities of AMs prescribed during 2012 and 2013 were higher than in 2011, suggesting increased use to treat disease in these years.
Health and production parameters
Milk yield on these farms remained stable over the study period, demonstrating that production was maintained alongside a cessation of HP-CIA use and an overall decrease in ADD prescribed through 2014-2015 (Fig 3) .
Before prescription policy changes made in 2011-2012, farmers would frequently treat cows that were systemically unwell due to retained fetal membranes or metritis with injectable third-generation cephalosporins. Subsequent to prescription policy changes, cattle with these diseases were treated with penicillin preparations or amoxicillin-clavulanic acid combinations. It is assumed that a significant deterioration in uterine health would have negative impacts on fertility parameters 33 34 ; however, no negative effects on fertility parameters were observed in association with the reduction in HP-CIAs on these farms; in fact, the calving index decreased, the 100-day in-calf rate increased and mean number of days from calving to conception showed a decreasing trend through 2010-2015 (Fig 4) .
The protocol for the antimicrobial treatment of endometritis (intrauterine first-generation cephalosporin licensed for this purpose in cattle) did not change on any of the farms throughout the study period. It is therefore unsurprising that the mean failure to cure rate of endometritis remained stable.
Mean clinical mastitis case rates are reported for reference (Fig 5A) , and it should be noted that they are lower than the average clinical mastitis case rates on farms in England and Wales (estimated to be 47 cases/100 cows/year (equating to a case rate of 0.47) 35 ). The increase in clinical mastitis case rate in 2012/2013 corresponds to the increase in prescription of AMs during these years and so is likely to contribute to the increased AM use in these years. Despite variation in clinical mastitis case rates throughout the six study years, the clinical mastitis cure rates improved, suggesting that the treatments being used through 2014 and 2015 (none of which contained HP-CIAs) appeared to be at least as effective at achieving a cure as the AMs being used in 2010, when 40 per cent of ADD of intramammary preparations prescribed contained HP-CIAs. This is consistent with a study in which implementation of a restricted AM usage policy in Dutch herds did not impact negatively on udder health. 36 HP-CIAs were not used in dry cow treatments in 2010; dry cow treatment protocols were therefore not changed between 2010 and 2015. The trend towards lower dry cow cure rates may be due to changes in mastitis pathogens, changes in dry cow management or in decreased efficacy of dry cow intramammary treatments, but it is difficult to differentiate between these with the data available.
Before prescription policy changes, infectious causes of lameness in milking cows (in particular interdigital necrobacillosis) would commonly have been treated with injectable third-generation cephalosporin preparations. Although primarily affected by management factors, lameness rates would be expected to have increased if infectious causes of lameness had a poor treatment recovery rate. The fact that mobility scores from all six farms for which there are data available shows a general reduction in the rates of lameness at mobility scores indicates that foot health can also be maintained alongside reduced HP-CIA use, specifically through the use of first-generation cephalosporins and aminopenicillins in place of thirdgeneration cephalosporins.
It is possible that animal health may have been deteriorating without altering the health parameters assessed if culling rates on the farms had increased significantly. Maximum culling rates through 2013-2015, however, were lower than those of 2010-2012, while the minimum culling rate remained at a similar level. Mean percentage change and associated CIs suggest that culling rates were maintained through all six years of the study (Fig 7) .
As this was a retrospective study, only health data and production parameters that were available from milk recording data and on-farm records could be analysed. Rather than assess the efficacy of specific treatment changes for particular diseases, this study sought to provide evidence about the effects on production and welfare parameters of reducing HP-CIAs on dairy farms. Where possible, individual animal treatment outcomes were assessed and presented. Although many treatment outcomes may be of interest (including clinical cure rates of pneumonia in calves or cases of interdigital necrobacillosis in dairy cows), not all of these could be assessed due to insufficient or inappropriate on-farm records. While calf health parameters were not directly assessed in these analyses, it should be noted that prescriptions of AMs classed as antipneumonials remained stable between 2010 and 2015 (both in kg and ADD).
Future work in this area should consider prospective evaluations of individual animal treatment outcomes for specific diseases over time as AM use changes, with consistent follow-up of cases and recording of clinical or bacteriological cures.
Changing prescribing practice
While HP-CIAs were used on all seven farms at the beginning of the study period, some farms had higher use than others, and the time taken to implement strategies to reduce HP-CIA use also varied between farms. This may reflect, in part, both the farmers' willingness to change AM use and individual VSs' willingness to alter on-farm treatment protocols or their own prescribing practice. The increasing uptake of prescribing changes through the study period may also reflect both farmers' and VSs' perception of responsible AM use, which may have been influenced by increasing public, political and industry pressures regarding AM use in agriculture during this time. Within two years of practice-wide implementation of prescribing changes, however, all six of the seven study farms that were clients of the FAP at the start of the study period had either significantly reduced or altogether ceased use of HP-CIAs. While changes on the majority of farms occurred over a period of time (one to two years), the farm that joined the practice at the end of 2013 (farm 6) changed its use of HP-CIAs with immediate effect after joining the practice and initiated use of SDCT, providing evidence that prescribing changes can be enacted quickly on farms. The changes to prescribing practice demonstrated in this study were made alongside various strategies to improve animal management and husbandry on the farms which subsequently resulted in a net decrease in doses (ADD) of AMs being prescribed, despite an increase in the use of certain AM classes. Through the results of this study, the authors propose that reducing the need to prescribe AMs by working to improve herd health, rather than forcibly avoiding the prescription or use of AMs, offers a sustainable way to safeguard animal health and welfare and maintain food production alongside reduced AM use. It should also be considered that reducing AM use through the process of improved herd health has many more economic advantages for the farm than purely changing or reducing AM use.
A cessation of the use of HP-CIAs and a decrease in the use of AMs within the livestock industry should be a key target for farmers and VSs and has been shown to be achievable while maintaining animal health, welfare and production.
Data and analyses of the sort presented here are crucial to addressing barriers that farmers and VSs face when deciding to alter their AM use and provide muchneeded evidence to aid a shift in the 'social norm' of AM use in production animal medicine.
Conclusions
This is the first study to demonstrate that dairy cattle health and welfare-as measured by culling rates, production parameters, fertility, udder health and mobility data-can be maintained, if not improved, alongside a complete cessation in the use of HP-CIAs as well as an overall reduction of AM use on dairy farms when prescribing practices are altered in line with proactive herd health planning strategies.
